Added to YB: 2026-09-18
Pitch date: 2026-09-16
BCRX [neutral]
BioCryst Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Market Cap
$2.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
5.90
P/E
-4.87
EV/Sales
2.73
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Week 2 Day 2 part 2 - BioCryst Pharmaceuticals, Inc.
BCRX (update): BioCryst has shifted from internal discovery toward external innovation, using ORLADEYO’s commercial foundation to support navenibart and a broader rare-disease platform; management’s 2030 goal is more than $1 billion of revenue from those two products and likely a third. Management says ORLADEYO continues to see its strongest demand nearly six years after launch, but the thesis depends on weathering new oral competition while awaiting Q3 2027 navenibart data and sourcing attractive external assets.
Read full article (2 min)